Skip Navigation
 
Publications

Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.

newspaper on a keyboard

Publications

Find an article or report or see all by area, author, or year:

Title:
Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections
Authors:
Brian N. Tse, Amesh A. Adalja, Christopher Houchens, Joseph Larsen, Thomas V. Inglesby, and Richard Hatchett
Publication:

Clinical Infectious Diseases, 2017;65(3):495–500

Publisher:
Oxford University Press for the Infectious Diseases Society of America
DOI:
10.1093/cid/cix320
Date posted:
April 17, 2017
See also:
Introduction:

Due to increasing rates of antimicrobial-resistant infections and the current inadequacy of the antibiotic pipeline, there is increasing interest in nontraditional approaches to antibacterial therapies. We define “traditional” agents as small-molecule agents that directly target bacterial components to exert a bacteriostatic or bactericidal effect, and “nontraditional approaches” as antimicrobial therapeutics that work through other means (ie, not a small molecule and/or utilizes a nontraditional target). Due to their atypical features, such therapies may be less susceptible to the emergence of resistance than traditional antibiotics. They include approaches such as monoclonal antibodies, virulence disruptors, immunomodulators, phage therapies, microbiome-based therapies, antibiotic potentiators, and antisense approaches. This article discusses both the developmental and regulatory advantages and challenges associated with each of these technologies. By identifying existing regulatory and developmental gaps, we hope to provide a sense of where focusing resources may provide the greatest impact on successful product development.